Role of aldo‐keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential

• Published in: Journal of cellular and molecular medicine Vol. 24; no. 16; pp. 8890 - 8902
• Main Authors: Khayami, Reza, Hashemi, Seyyed Reza, Kerachian, Mohammad Amin
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.08.2020; John Wiley and Sons Inc
• Subjects: AKR1B1; AKT protein; Aldehyde Reductase - metabolism; aldose reductase; Animals; Antineoplastic Agents - pharmacology; Apoptosis; Binding sites; biomarker; Biomarkers, Tumor - metabolism; Cancer; Cell cycle; Cell survival; Colorectal cancer; Cyclins; DNA methylation; Enzyme Inhibitors - pharmacology; Enzymes; Glucose; Growth factors; Humans; Inflammation; Kinases; Lipid peroxidation; Lipids; Lymphocytes B; Mesenchyme; Metabolism; Metastasis; methylation; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; NF-κB protein; Proteins; Rapamycin; Reactive oxygen species; Reductase; Review; Reviews; Signal transduction; TOR protein; Tumor necrosis factor-TNF; Tumorigenesis; Tumors; tumour; aldose reductase; AKR1B1; cancer; biomarker; methylation; tumour

The role of aldo‐keto reductase family 1 member B1 (AKR1B1) in cancer is not totally clear but growing evidence is suggesting to have a great impact on cancer progression. AKR1B1 could participate in a complicated network of signalling pathways, proteins and miRNAs such as mir‐21 mediating mechanism...